PRODUCT MONOGRAPH

FLUMAZENIL INJECTION

Injectable Solution

0.1 mg/mL

USP

Benzodiazepine Antagonist

Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8

Control No.: 183350

Date of Preparation: April 15, 2015
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3
  SUMMARY PRODUCT INFORMATION .................................................................3
  INDICATIONS AND CLINICAL USE .......................................................................3
  CONTRAINDICATIONS .............................................................................................3
  WARNINGS AND PRECAUTIONS ..........................................................................4
  ADVERSE REACTIONS .............................................................................................6
  DRUG INTERACTIONS ...............................................................................................8
  DOSAGE AND ADMINISTRATION .........................................................................8
  OVERDOSAGE .........................................................................................................9
  ACTION AND CLINICAL PHARMACOLOGY ..........................................................9
  STORAGE AND STABILITY .......................................................................................11
  DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................12

PART II: SCIENTIFIC INFORMATION ........................................................................13
  PHARMACEUTICAL INFORMATION .....................................................................13
  DETAILED PHARMACOLOGY ...............................................................................13
  TOXICOLOGY .........................................................................................................17
  REFERENCES ..........................................................................................................23

PART III: CONSUMER INFORMATION ......................................................................25
INDICATIONS AND CLINICAL USE
Flumazenil Injection, USP is indicated for the complete or partial reversal of the central sedative effects of benzodiazepines. It may therefore be used in anesthesia and intensive care in the following situations:

- termination of general anesthesia induced and/or maintained with benzodiazepines;
- reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures;
- for the diagnosis and/or management of deliberate or accidental benzodiazepine overdose.

Pediatrics: No data available.

Geriatrics: No data available.

CONTRAINDICATIONS
Flumazenil Injection, USP is contraindicated:

- in patients with known hypersensitivity to flumazenil or to benzodiazepines;
- in epileptic patients who have been receiving benzodiazepine treatment for a prolonged period. The abrupt suppression of the protective effect of benzodiazepines may induce convulsions in epileptic patients;
- in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS AND PRECAUTIONS);
- in patients who have been given a benzodiazepine for a potentially life-threatening condition (e.g., intracranial pressure).
WARNINGS AND PRECAUTIONS

- In view of the short duration of action of flumazenil and the possible need for repeat doses, the patient should remain closely monitored until all possible central benzodiazepine effects have subsided.
- The immediate availability of oxygen, resuscitative equipment and skilled personnel for the maintenance of airway, ventilation and cardiac function should be ensured before the administration of any benzodiazepine or flumazenil.

General

In high-risk patients, the advantages of counteracting benzodiazepine-related sedation should be weighed against the drawbacks of rapid awakening.

Postoperative pain must be taken into account. Following a major intervention, it may be preferable to maintain a moderate degree of sedation.

Flumazenil is not recommended either as a treatment for benzodiazepine dependence or for the management of protracted benzodiazepine abstinence syndromes.

Resedation: Flumazenil is a competitive inhibitor of benzodiazepines at the receptor site and does not affect the pharmacokinetics of benzodiazepines. Thus, when the effect of flumazenil wears off, the patient returns to the point of residual sedation that would have been present at that time had flumazenil not been given. In patients administered large doses of long-acting benzodiazepines or in critically ill patients, this could be deep sedation. In a U.S. clinical study in patients with benzodiazepine intoxication, 90/133 (67.7%) patients became resedated. Therefore, flumazenil should be administered only when the continued observation of patients for recurrence of sedation can be assured.

Seizures: In patients treated for long periods of time and/or with high doses of benzodiazepines, flumazenil may trigger withdrawal symptoms (e.g., convulsions, agitation, anxiety, emotional lability as well as mild confusion and sensory distortions); rapid intravenous injections should therefore be avoided. Seizures have been reported in patients known to suffer from epilepsy, or severe hepatic impairment, particularly after long-term treatment with benzodiazepines or in cases of mixed-drug overdose.

Anxiety: The dosage of flumazenil should be adjusted carefully in patients suffering from pre-operative anxiety or having a history of chronic or episodic anxiety. In anxious patients, particularly those with coronary heart disease, it is preferable to maintain a degree of sedation throughout the early postoperative period rather than bring about complete arousal.

Instructions to Patients Upon Discharge: Patients who have received flumazenil to reverse the effects of benzodiazepine sedation should be instructed, if possible in writing, not to drive, operate machinery or engage in any other physically or mentally demanding activity for 24 hours or until the effects of the benzodiazepine have subsided, since the effect of the benzodiazepine
may return. Patients should also be warned not to take alcohol, or drugs not prescribed by their physician, until the effects of the benzodiazepines have subsided.

**Use in Patients with Increased Intracranial Pressure Receiving Benzodiazepines (e.g., head injury, brain tumour, intracranial hemorrhage):** In patients with increased intracranial pressure, flumazenil may further increase intracranial pressure and decrease cerebral perfusion pressure, or precipitate convulsions. In such patients, flumazenil should be used with extreme caution and only by practitioners prepared to manage such complications, should they occur.

**Multiple-drug Overdosage:** Particular caution is necessary when using flumazenil in cases of multiple-drug overdosage, since the toxic effects (cardiac arrhythmias and/or convulsions) of other psychotropic drugs, especially cyclic antidepressants, may increase as the effects of benzodiazepines subside.

Patients should be evaluated for the signs and symptoms (autonomic, neurological or cardiovascular) of a cyclic antidepressant overdose. A diagnostic ECG can be used to confirm the presence of these agents; a QRS duration of 0.1 second or greater indicates a serious overdosage with cyclic antidepressants, which should be treated with appropriate measures. Depending on the extent of involvement of benzodiazepines in the multiple-drug overdose, this may or may not include flumazenil.

**Use in the ICU:** Flumazenil should be used with caution in the Intensive Care Unit because of the increased risk of unrecognized benzodiazepine dependence in such settings. Flumazenil may produce convulsions in patients physically dependent on benzodiazepines (see WARNINGS AND PRECAUTIONS, General, Seizures).

**Respiratory**

When used in anesthesiology at the end of surgery, flumazenil should not be given until the effects of neuromuscular blockade have been completely antagonized and careful monitoring of the respiratory depressant effect of opiate analgesics has been assured. After the benzodiazepine has been antagonized with flumazenil, any residual respiratory depressant effect of other agents, such as opiates, should be appropriately treated.

The ability of flumazenil to reverse benzodiazepine-induced respiratory depression is equivocal; in some studies, residual effects of benzodiazepines on respiration were still present despite reversal of sedation.

**Cardiovascular**

Flumazenil abruptly terminates the effects of benzodiazepines. As a result, sympathetic tone may be increased and thus, cardiac electrical instability enhanced. Consequently, caution is advised when administering flumazenil to patients with myocardial infarction or cardiac arrhythmias.
Hepatic/Renal

In patients with liver insufficiency, the elimination of flumazenil can be delayed (see ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics). No dosage adjustments are necessary in patients with renal impairment. Seizures have been reported in patients known to suffer from severe hepatic impairment, particularly after long-term treatment with benzodiazepines or in cases of mixed-drug overdose.

Special Populations

Pediatrics (< 18 years of age): The safety and effectiveness of flumazenil in children below the age of 18 have not been established.

Geriatrics: In the absence of data on the use of flumazenil in elderly patients, it should be borne in mind that this population is generally more sensitive to the effects of drugs and should be treated with due caution.

Pregnant Women: Although studies in animals have not shown evidence of embryotoxicity or teratogenicity (see TOXICOLOGY, Reproduction and Teratology), flumazenil should be used during pregnancy only, if in the opinion of the treating physician, the possible benefit to the patient outweighs the potential risks to the fetus.

Nursing Women: It is not known whether flumazenil is excreted in human milk. For this reason, breast-feeding should be interrupted for 24 hours when flumazenil is used during lactation.

ADVERSE REACTIONS

Flumazenil is generally well tolerated. In postoperative use, nausea and/or vomiting are observed, particularly if opiates have also been employed. Flushing has also been noted. If patients are awakened too rapidly, they may become agitated, anxious or fearful. Transient increases in blood pressure and heart rate may also occur.

Excessively and/or rapidly injected doses of flumazenil may induce benzodiazepine withdrawal symptoms such as anxiety attacks, tachycardia, dizziness, and sweating in patients on long-term benzodiazepine treatment.

Although clinical experience with flumazenil is limited, seizures and/or cardiac arrhythmias have been observed in patients who are physically dependent on benzodiazepines, and in multiple-drug overdose, particularly in the presence of tricyclic antidepressants.

Flumazenil has been reported to provoke panic attacks in patients with a history of panic disorders.
The following table summarizes the adverse reactions which occurred with an incidence of > 1%.

**Clinical Adverse Events > 1%**

<table>
<thead>
<tr>
<th>Organ System</th>
<th>Adverse Events</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>General Anesthesia/ Sedation n = 7,365</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>Agitation</td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>Crying/Tears</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>Anxiety/Anxious Feeling</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>Seizures/Convulsions</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Dizziness</td>
<td>1.4</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Nausea</td>
<td>4.3</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>2.6</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Hypertension</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>Tachycardia</td>
<td>0.1</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Shivering/Cold Sensation/Chills</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Other clinical adverse events which occurred with an incidence of < 1% are as follows:

**Cardiovascular:** Ventricular premature beats, arrhythmia, palpitations, bradycardia, flush, hypotension;

**Respiratory:** Dyspnea, hypopnea, nasal congestion, cough, subjective suffocation;

**CNS/Neuromuscular:** Startle reaction, fear, nervousness, restlessness, excitation, aggressiveness, anger; euphoria, hallucinations, vertigo, confusion, tiredness/drowsiness, depression; involuntary/spontaneous movement, tremor, mouth movement, tetany;

**Gastrointestinal:** Salivation, dry mouth, hiccoughs;

**Dermatological:** Urticaria, pruritus;

**Miscellaneous:** Pain, allergic reaction, strabismus, sweating;

**Local Tolerance:** Slight to moderate pain at the site of injection occurred in 2.5% of patients and redness was observed in 1.3% of patients one hour after the administration of flumazenil.
DRUG INTERACTIONS

Flumazenil blocks the central effects of benzodiazepines by competitive interaction at the receptor level; the effects of non-benzodiazepines which act via the benzodiazepine receptor, such as zopiclone, triazolopyridazines and others, are also blocked. However, flumazenil does not reverse the effects of drugs that do not act via this route.

The pharmacokinetics of flumazenil are unaltered in the presence of benzodiazepines, and similarly, flumazenil does not affect the kinetics of benzodiazepines.

There is no pharmacokinetic interaction between ethanol and flumazenil.

DOSAGE AND ADMINISTRATION

Flumazenil should be administered intravenously by a physician with experience in anesthesiology.

The dose of flumazenil should always be individually titrated to the desired response to avoid abrupt awakening. Particular care is needed with patients who are physically dependent on benzodiazepines, patients who have ingested multiple drugs, and patients who are prone to anxiety. In the intensive care unit, in patients treated with high doses of benzodiazepines and/or for long periods of time, the individually titrated injections of flumazenil, slowly administered, should not produce withdrawal syndromes (see WARNINGS AND PRECAUTIONS). If unexpected symptoms occur, diazepam or midazolam could be carefully titrated intravenously according to patient’s response.

Flumazenil may be used concurrently with other resuscitative procedures.

Flumazenil Injection, USP may be diluted in a glass bottle to a final concentration of 0.05 mg/mL with 0.9% Sodium Chloride Injection, 0.45% Sodium Chloride and 2.5% Dextrose Injection, 5% Dextrose Injection, or Lactated Ringer’s Injection (see STORAGE AND STABILITY).

Reversal of General Anesthesia/Sedation

The recommended initial dose is 0.2 mg administered intravenously over 15 seconds. If the desired level of consciousness is not obtained within 60 seconds, a further dose of 0.1 mg can be injected and repeated at 60-second intervals, up to a maximum total dose of 1 mg. The usual dose is between 0.3 and 0.6 mg.

Known or Suspected Benzodiazepine Overdose

For the reversal of excessive sedative effects of benzodiazepines in overdose cases, titrate flumazenil as described below, until the patient clearly responds or until the maximum recommended dose has been reached.

The recommended initial dose is 0.3 mg administered intravenously over 30 seconds, followed by a series of 0.3 mg injections, each administered over a 30-second period, at 60-second intervals. The maximum recommended dose is 2.0 mg.
If a significant improvement in the level of consciousness and respiratory function is not achieved after repeated injections of flumazenil, a non-benzodiazepine etiology must be assumed.

If drowsiness recurs, an intravenous infusion of 0.1 – 0.4 mg/hr may be useful. The rate of the infusion should be individually adjusted to the desired level of arousal.

**OVERDOSAGE**

Flumazenil, administered intravenously to healthy volunteers at a dosage of 100 mg, did not produce symptoms of overdosage.

**ACTION AND CLINICAL PHARMACOLOGY**

**Mechanism of Action**

Flumazenil, an imidazobenzodiazepine, is a benzodiazepine antagonist which blocks the central effects of agents that act via the benzodiazepine receptor, by competitive inhibition. The antagonism is specific, since in animal experiments the effects of compounds which have no affinity for the benzodiazepine receptor (e.g., barbiturates, meprobamate, ethanol, GABA-mimetics, and adenosine receptor agonists) were not affected by flumazenil.

Following the intravenous administration of radiolabelled flumazenil to human volunteers, the distribution of radioactivity corresponded closely to the distribution of benzodiazepine receptors as determined by positron emission tomography.

The hypnotic-sedative effects of benzodiazepines are rapidly reversed by flumazenil. However, the residual effects may reappear gradually within a few hours, depending on the dose of flumazenil, the time elapsed since the benzodiazepine agonist was given, and the dose and elimination half-life of the previously administered benzodiazepine. Flumazenil has shown some weak intrinsic agonistic (e.g., anticonvulsant) activity without therapeutic relevance.

**Pharmacokinetics**

In young male volunteers, the pharmacokinetics of intravenous flumazenil were linear over a dose range of 2 –100 mg. Increasing doses of flumazenil were accompanied by a corresponding increase in the area under the plasma concentration-time curve (AUC: 37 ng/mL•hr at 2 mg and 1,906 ng/mL•hr at 100 mg), and maximum plasma concentration (C_max: 55 ng/mL at 2 mg and 3,332 ng/mL at 100 mg). However, elimination half-life, volume of distribution at steady state, and plasma clearance were independent of dose over the entire range studied. The mean elimination half-life of flumazenil following the administration of single intravenous doses to healthy subjects was approximately one hour.

The following table summarizes the ranges of mean pharmacokinetic parameters reported in a series of studies, after single intravenous doses of flumazenil.
<table>
<thead>
<tr>
<th>Subjects</th>
<th>Dose (mg)</th>
<th>Elimination Half-life ($t_{1/2}$) (min)</th>
<th>Volume of Distribution at Steady State ($V_{dss}$) (L/kg)</th>
<th>Plasma Clearance ($Cl_{pl}$) (L/hr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male volunteers 23-26 years</td>
<td>2 - 100</td>
<td>48 - 55</td>
<td>0.83 - 0.86</td>
<td>55 - 57</td>
</tr>
<tr>
<td>Male volunteers 28-42 years</td>
<td>2.5</td>
<td>42 - 72</td>
<td>0.63</td>
<td>41</td>
</tr>
<tr>
<td>Volunteers 39 years</td>
<td>2</td>
<td>46</td>
<td>0.62</td>
<td>74</td>
</tr>
<tr>
<td>Cirrhosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- moderate 45 years</td>
<td>2</td>
<td>76</td>
<td>0.68</td>
<td>29</td>
</tr>
<tr>
<td>- severe 45 years</td>
<td>2</td>
<td>142</td>
<td>0.85</td>
<td>19</td>
</tr>
<tr>
<td>Volunteers 37 years</td>
<td>1</td>
<td>51</td>
<td>0.91</td>
<td>60</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- without dialysis 36 years</td>
<td>1</td>
<td>38</td>
<td>0.94</td>
<td>75</td>
</tr>
<tr>
<td>- with dialysis 55 years</td>
<td>1</td>
<td>43</td>
<td>1.07</td>
<td>75</td>
</tr>
<tr>
<td>Age Volunteers:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 - 28 years</td>
<td>2</td>
<td>54</td>
<td>0.87</td>
<td>56</td>
</tr>
<tr>
<td>65 - 77 years</td>
<td>2</td>
<td>66</td>
<td>0.93</td>
<td>56</td>
</tr>
<tr>
<td>Female:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 - 30 years</td>
<td>2</td>
<td>48</td>
<td>0.96</td>
<td>66</td>
</tr>
<tr>
<td>63 - 67 years</td>
<td>2</td>
<td>54</td>
<td>0.78</td>
<td>44</td>
</tr>
</tbody>
</table>

When administered together with the benzodiazepines, midazolam, flunitrazepam or lormetazepam, the pharmacokinetic parameters of flumazenil were not affected. Similarly, the pharmacokinetics of benzodiazepines remained unaltered in the presence of the antagonist flumazenil.

**Distribution:** Plasma protein binding is rather low. Over a concentration range of 24 to 570 ng/mL, flumazenil was found to be 50% bound to human plasma proteins. Albumin accounts for approximately two-thirds of the plasma protein binding. The binding of flumazenil was not affected by a high concentration of diazepam (10 mcg/mL), and flumazenil did not interfere with the binding of diazepam.

**Metabolism/Excretion:** Flumazenil undergoes rapid and extensive hepatic metabolism; less than 0.2% of the administered dose is eliminated unchanged in the urine. The major metabolites of flumazenil identified in the urine are the free acid and its glucuronide conjugate. In healthy volunteers, approximately 70% of an intravenous dose of flumazenil was excreted within the first two hours after dosing and another 16% during the next two hours. Elimination was essentially complete within 72 hours, with 90 to 95% of the total radioactivity appearing in the urine and 5 to 10% in the feces.

Ingestion of food during an intravenous infusion of flumazenil results in a 50% increase in clearance, most likely due to the increased hepatic blood flow that accompanies a meal.
**Special Populations and Conditions**

**Geriatrics:** There were no statistically significant differences between the distribution and elimination parameters of 12 elderly (8 males and 4 females) and 6 young (4 males and 2 females) healthy volunteers, following the administration of a 2 mg intravenous dose.

**Hepatic Insufficiency:** In patients with cirrhosis, the pharmacokinetics of flumazenil were altered, particularly in patients with severely impaired liver function. Elimination half-life was prolonged and plasma clearance markedly decreased. Since plasma protein binding is lower in cirrhotic patients than in healthy subjects, the levels of free drug are substantially increased, namely from 55% in controls to 64% and 79% in patients with moderate and severe liver dysfunction, respectively.

**Renal Insufficiency:** In patients with chronic stabilized renal failure (creatinine clearance < 10 mL/min) in the absence and presence of dialysis, the pharmacokinetics of flumazenil remained essentially unaltered.

**STORAGE AND STABILITY**

Flumazenil Injection, USP should be stored between 15 °C and 30 °C.

Multiple-dose vial. Discard unused portion 28 days after initial puncture.

**Stability and Storage of Diluted Solutions**

Flumazenil Injection may be diluted in glass bottle to a final concentration of 0.05 mg/mL with 0.9% Sodium Chloride Injection, 0.45% Sodium Chloride and 2.5% Dextrose Injection, 5% Dextrose Injection, or Lactated Ringer’s Injection. Infusion solutions containing flumazenil should be used within 24 hours, and unused portions discarded.

As with all parenteral drug products, intravenous admixtures should be inspected visually for clarity, particulate matter, precipitate, discolouration and leakage prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discolouration or leakage should not be used. Discard unused portion.
DOSAGE FORMS, COMPOSITION AND PACKAGING

Flumenazil Injection, USP is a sterile aqueous solution for intravenous injection. Each mL of the colourless aqueous solution contains: 0.1 mg flumazenil, 1.8 mg methylparaben, 0.2 mg propylparaben, 0.1 mg disodium edetate, 9.0 mg sodium chloride and 0.1 mg acetic acid; sodium hydroxide and hydrochloric acid added to adjust pH to approximately 4, and Water for Injection.

Flumazenil Injection, USP is supplied in multiple-dose vials:

Product Code:

C402405  5 mL fill in a 6.5 mL vial - packaged in trays of 10 vials
C402410  10 mL fill in a 10 mL vial - packaged individually.

Vial stoppers do not contain natural rubber latex.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: flumazenil

Chemical Name: ethyl-8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4] benzodiazepine-3-carboxylate

Molecular Formula and Molecular Mass: C_{15}H_{14}FN_{3}O_{3}; 303.3

Structural Formula:

![Structural Formula of Flumazenil](image)

Description: Flumazenil is a white to off-white crystalline powder with a faint odour. It is slightly soluble in methyl alcohol and practically insoluble in water. Melting range is 198-202°C. pKa = 1.7

DETAILED PHARMACOLOGY

Receptor Studies

Using $^3$H-flumazenil, a benzodiazepine antagonist or $^3$H-clonazepam, a benzodiazepine agonist as radioligands in *in vitro* binding studies, a variety of receptor agonists showed very similar potency in inhibiting the binding of either ligand.

<table>
<thead>
<tr>
<th>Ligand</th>
<th>$^3$H-flumazenil binding</th>
<th>$^3$H-clonazepam binding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agonists</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- clonazepam</td>
<td>1.4</td>
<td>1.2</td>
</tr>
<tr>
<td>- flunitrazepam</td>
<td>4.8</td>
<td>5.1</td>
</tr>
<tr>
<td>- diazepam</td>
<td>19.5</td>
<td>13.5</td>
</tr>
<tr>
<td>- zopiclone</td>
<td>50</td>
<td>46</td>
</tr>
<tr>
<td>Antagonist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- flumazenil</td>
<td>1.3</td>
<td>2.0</td>
</tr>
</tbody>
</table>
Flumazenil also displaced $^3$H-flunitrazepam under *in vitro* conditions. The ED$_{50}$ was 4.0 mg/kg p.o. when mice were sacrificed 15 minutes after the administration of flumazenil.

Autoradiography studies have revealed that while $^3$H-flunitrazepam binds to both central and peripheral benzodiazepine receptor sites, $^3$H-flumazenil binds only to central receptor sites. This suggests that flumazenil will antagonize only those effects of the benzodiazepines that are mediated via the central nervous system.

While flumazenil interacts with the same number of benzodiazepine receptor sites as the benzodiazepines, the mode of interaction of the antagonist and agonists differs. Under conditions which alter receptor affinity for agonists, no change is seen in $^3$H-flumazenil binding. Specifically, (a) in the presence of GABA, benzodiazepine receptor affinity is enhanced for agonists, but remains unchanged for flumazenil; (b) in the presence of photoaffinity labelling, benzodiazepine receptor affinity is attenuated for agonists, but remains unchanged for flumazenil.

In conclusion, similar to benzodiazepine agonists, flumazenil interacts with central benzodiazepine receptors in nanomolar concentrations, the inhibition of agonist binding by flumazenil being competitive. Unlike the agonists, flumazenil is insensitive to GABA or photoaffinity labeling-induced changes in receptor affinity.

**Benzodiazepine Antagonist Activity**

Flumazenil potently antagonizes the centrally-mediated pharmacological effects of various benzodiazepines. In the table below, only the minimal effective doses are described, but flumazenil exerts its effects in a dose-dependent fashion.
### Antagonism of Benzodiazepines in Neurological and Behavioural Studies

<table>
<thead>
<tr>
<th>Test Performed (species)</th>
<th>Benzodiazepine</th>
<th>Flumazenil</th>
<th>Minimal Effective Dose mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Traction test (mice)</td>
<td>muscle relaxation</td>
<td>diazepam 3 i.p.</td>
<td>reversal</td>
</tr>
<tr>
<td>Pentylenetrazole-induced convulsions (mice)</td>
<td>antagonism of convulsions</td>
<td>diazepam 5 i.p.</td>
<td>reversal</td>
</tr>
<tr>
<td>Hexobarbital-induced loss of righting reflex (mice)</td>
<td>potentiation</td>
<td>meclonazepam 1 i.p.</td>
<td>reversal</td>
</tr>
<tr>
<td>Locomotor activity (rats)</td>
<td>hypomotility</td>
<td>diazepam 30 p.o.</td>
<td>reversal</td>
</tr>
<tr>
<td>Open field behaviour (rats)</td>
<td>reduced exploration and rearing</td>
<td>meclonazepam 10 p.o.</td>
<td>reversal</td>
</tr>
<tr>
<td>Conflict behaviour (rats)</td>
<td>attenuation of conflict</td>
<td>diazepam 5 p.o.</td>
<td>reversal</td>
</tr>
<tr>
<td>Behavioural observation (dogs)</td>
<td>ataxia</td>
<td>meclonazepam 3 p.o.</td>
<td>prevention</td>
</tr>
<tr>
<td>Behavioural observation (squirrel monkeys)</td>
<td>sedation, anesthesia</td>
<td>flunitrazepam 3 i.v. midazolam 10 i.v.</td>
<td>reversal</td>
</tr>
<tr>
<td>Cognition (mice)</td>
<td>induction of anterograde amnesia</td>
<td>triazolam 1 p.o.</td>
<td>reversal</td>
</tr>
<tr>
<td>Electrophysiological studies “encéphale isolé” (rats)</td>
<td>reduced cell firing in several central regions</td>
<td>midazolam 0.1-10 mcmol/kg i.v. (0.3-3 mg/kg)</td>
<td>recovery of cell firing</td>
</tr>
<tr>
<td>Acute spinal cats</td>
<td>enhancement &amp; prolongation of dorsal root potentials</td>
<td>meclonazepam 0.1 i.v.</td>
<td>prevention &amp; reversal</td>
</tr>
<tr>
<td>Respiratory study (rabbits)</td>
<td>reduced respiratory min. volume &amp; rate of respiration</td>
<td>diazepam 0.1 i.v. flunitrazepam 0.03 i.v.</td>
<td>reversal</td>
</tr>
</tbody>
</table>

The ability of flumazenil to antagonize benzodiazepine agonists is specific for this class of drugs. The muscle relaxant, anticonvulsant, and anticonflict effects of phenobarbital, meprobamate, and
ethanol were not antagonized by flumazenil. Flumazenil was also inactive against scopolamine or hypercapnia-induced anterograde amnesia and morphine-induced respiratory depression.

**Flumazenil-induced Withdrawal**

Flumazenil, administered i.v., i.m., or p.o., elicited typical benzodiazepine withdrawal signs in mice, rats, cats, and squirrel monkeys, following chronic administration of benzodiazepines (12 to 35 days). The symptoms included emesis, vocalization, tremors, rigidity, and convulsions. The type of withdrawal symptoms and their intensity depended upon the dose and duration of benzodiazepine treatment, as well as the time of flumazenil administration *vis à vis* the last dose of the benzodiazepine.

**Intrinsic Activity**

Flumazenil did not affect normal behaviour in rats, dogs, or squirrel monkeys in doses of up to 100 mg/kg. Similarly, motor activity, conditioned avoidance behaviour, conflict behaviour in rats and continuous avoidance behaviour in squirrel monkeys remained unchanged when flumazenil was given in doses of up to 100 mg/kg p.o. These findings indicate that flumazenil is devoid of benzodiazepine agonist activity at doses that are substantially higher than those which exert antagonist activity.

**Inverse Agonist Activity**

A group of benzodiazepine receptor ligands, classified as "inverse agonists" cause opposite effects to those of the benzodiazepine receptor agonists, namely they produce convulsions and anxiety in appropriate animal models.

Flumazenil did not induce convulsions, except at sublethal doses. However, it did exert weak anxiogenic activity in several behavioural animal models, namely in the “social interaction” and “conditioned spatial aversion” tests, as well as in various conflict situations. Active doses ranged from 4 to 30 mg/kg i.p. or p.o.

**Cardiovascular Effects**

Flumazenil did not affect blood pressure or heart rate either in spontaneously hypertensive rats (maximum dose 100 mg/kg p.o.) or in renal hypertensive dogs (maximum dose 30 mg/kg p.o.).
### Acute Toxicity

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Species</th>
<th>Sex</th>
<th>LD₅₀ (mg/kg)</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>i.v.</td>
<td>mice</td>
<td>male</td>
<td>159-168</td>
<td>Deaths, preceded by tonic-clonic convulsions, occurred within 30 minutes of dosing. Surviving animals were hypoactive, and manifested respiratory depression and increased muscle tone.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>female</td>
<td>132-159</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rats</td>
<td>male</td>
<td>119-134</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>female</td>
<td>161-182</td>
<td></td>
</tr>
<tr>
<td>i.p.</td>
<td>mice</td>
<td>male</td>
<td>&gt; 2,000</td>
<td>Deaths occurred within three days of dosing. Most animals were hypoactive, and manifested catatonia, tremors, salivation, lacrimation and respiratory depression.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>female</td>
<td>1,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rats</td>
<td>male</td>
<td>2,200</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>female</td>
<td></td>
<td></td>
</tr>
<tr>
<td>s.c.</td>
<td>mice</td>
<td>male &amp; female</td>
<td>&gt; 1,000</td>
<td></td>
</tr>
<tr>
<td>p.o.</td>
<td>mice</td>
<td>male</td>
<td>2,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>female</td>
<td>1,300</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rats</td>
<td>male &amp; female</td>
<td>4,200</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>female</td>
<td>2,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rabbits</td>
<td>male &amp; female</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Intravenous Pyramiding Dose Toxicity in Dogs:

Three groups of four dogs each (2/sex) received (a) flumazenil at doses of 0.01, 0.03, 0.1, and 0.3 mg/kg; (b) pyramiding doses of the vehicle (0.1, 0.3, 1.0, and 3.0 mL/kg) and; (c) equivalent volumes of physiological saline. The dogs were dosed twice a week over a two-week period. All dogs survived the pyramiding doses of flumazenil and were essentially asymptomatic throughout the study. Flumazenil did not affect body weight, food intake, hematological or clinical chemical parameters.

### Long-Term Toxicity Studies

1. **Two-Week Intravenous – Rats:**

Flumazenil was injected i.v. into the tail vein of rats (8/sex/group) at doses of 0, 1, 3, and 10 mg/kg/day.

Tissue irritation at the injection site was pronounced and dose-related. At the low dose, local tolerance was acceptable. At the mid-dose, all rats had swollen and reddened tails beginning with the third dose and continuing to the end of the study. At the high dose, intolerance at the
injection site was severe. Hematomas occurred in five of eight males and one female rat. Two of eight male rats in the high-dose group also showed ulceration of the tail, and in three male rats the administration of the drug had to be performed intraperitoneally on the fifth day. In general, female rats tolerated the treatment better than male animals. Pronounced bleeding at the injection site was also observed in most of the mid- and high-dose animals beginning about the fifth day of the study.

At the 10 mg/kg dose, male rats gained weight at a slower rate than male controls; this effect was considered to be treatment-related. A similar effect in female rats was equivocal.

2. **Two-Week Oral – Rats:**

Flumazenil was administered by gavage to rats (8/sex/group) at doses of 0, 5, 25, and 150 mg/kg/day. The drug was given for 15 or 16 consecutive days to female and male rats, respectively.

Flumazenil was devoid of toxic effects at the doses studied.

3. **Two-Week Intravenous – Dogs:**

Flumazenil was injected i.v. to beagle dogs (2/sex/group) at doses of 0, 1, 3, and 10 mg/kg/day. The mid-dose produced drowsiness and the high dose produced drowsiness and ataxia; both effects were observed following dosing. In the course of the study, a slight tolerance did develop to these effects.

Injections were poorly tolerated in the dogs receiving 10 mg/kg of flumazenil, due to hardened and thrombosed veins and a strong defence reaction from the animals.

In the high-dose group, reticulocytes were significantly increased in the second week of the study in comparison to the control group. Platelets were decreased in all treated groups *vis à vis* baseline values, but the changes were not dose-related. A statistically significant increase in the relative liver weights was noted in the high-dose group, this effect was considered to be treatment-related.

4. **Two-Week Oral – Dogs:**

Flumazenil was administered in capsules to beagle dogs (2/sex/group) at doses of 0, 5, 20, and 80 mg/kg/day for 15 consecutive days.

Slight diarrhea was noted at the 20 mg/kg dose and marked diarrhea (sometimes bloody) at the 80 mg/kg dose. Mean spleen weights were decreased and mean liver weights increased in all flumazenil-treated dogs. At necropsy, the tunica mucosa of the colon was more convoluted in high-dose animals than in controls.
5. **Four-Week Intravenous – Rats:**

Flumazenil was injected i.v. into the tail vein of rats (12/sex/group) at doses of 0, 1, 3, and 10 mg/kg/day.

Local tolerance to the i.v. injections was poor and the degree of swelling and pain was dose-related. At the high-dose, the route of administration had to be switched from intravenous to intraperitoneal about 15 days after the beginning of the study.

In male rats, there was a dose-related weight gain deficit. Although the mean values remained within the normal range, WBC counts decreased in male rats in a dose-related fashion at week 4. The decrease seen in the high-dose group was statistically significant. Both absolute and relative liver weights were increased in high-dose female rats. Perilymphadenitis was seen in high-dose males and females, this might have been due to the intraperitoneal injections. One high-dose female rat had a moderate degenerative change in the retina.

6. **Four-Week Intravenous – Dogs:**

Flumazenil was injected i.v. to beagle dogs (2/sex/group) at doses of 0, 1, 3, and 10 mg/kg/day.

Mid-dose dogs were sedated and high-dose dogs showed both sedation and ataxia. Tolerance did not develop to these effects. WBC counts decreased slightly. While the mean values were within normal range, in a few dogs they fell below normal. Local tolerance (injection site) was poor in the high-dose groups as also shown by high inflammation scores.

7. **Thirteen-Week Oral – Rats:**

Flumazenil was administered in the diet to rats (18/sex/group) at doses of 0, 5, 25, and 125 mg/kg/day.

In female rats, liver weights were somewhat elevated in the high-dose group, and thyroid weights slightly decreased in a dose-related fashion.

8. **Thirteen-Week Oral – Dogs:**

Flumazenil was administered in capsules to beagle dogs, (3/sex/group), seven days/week, at doses of 0, 5, 20, and 80 mg/kg/day.

Slight sedation, lasting 1-3 hours following dosing was noted in the high-dose group; tolerance did not develop to this effect. Weight gain in high-dose animals was somewhat attenuated when compared to controls. At week 12, heart rate was increased in high-dose dogs, *vis à vis* both baseline and control dogs. There was a dose-related decrease in both absolute and relative spleen weights.
9. **Twelve-Month Oral – Rats:**

Flumazenil was administered in the diet to rats (20-30/sex/group) at doses of 0, 6, 20, and 125 mg/kg/day. An interim sacrifice of ten control rats (5/sex) and ten rats from the high-dose group (5/sex) was carried out at six months.

Hemoglobin, erythrocyte and hematocrit values were slightly lower in treated male animals than in controls, throughout the study. In females, these parameters were reduced only at six months.

At six months, both absolute and relative thyroid weights in high-dose males, and liver weights in high-dose females were significantly increased. Histopathological evaluation revealed a slight to moderate congestion in the liver of all females treated with the high dose.

At twelve months, absolute and relative thyroid weights were slightly decreased in low- and mid-dose males, but increased in high-dose animals. Liver weights and histopathological findings were similar in treated and control rats.

**Mutagenicity**

Flumazenil had no mutagenic activity in six out of seven mutagenicity assays (Ames test, Treat and Plate test, gene mutation, *in vivo* and *in vitro* clastogenicity and *in vivo* DNA repair). In a UDS assay, there was a dose-dependent unscheduled incorporation of $^3$H-thymidine in nuclear DNA of rat hepatocytes after treatment with flumazenil concentrations of 252, 504, and 1,010 mcg/mL for eighteen hours. However, the increase could only be shown at substance concentrations that were also cytotoxic. Since there were no effects in the absence of cytotoxicity, interactions between cytotoxic, and DNA-damaging effects, resulting in repair processes, cannot be excluded.

**Reproduction and Teratology**

1. **Fertility and General Reproductive Performance:**

In a Segment I study, flumazenil was administered by gavage to rats in doses of 0, 15, 45, and 125 mg/kg/day. Thirty-two males per group were treated for 10 weeks prior to mating and during the mating period. The treatment of 32 females per group started two weeks prior to mating and continued through the gestation and lactation periods. No mortality or adverse effects were observed on parental animals.

Mating success, gestation length, and outcome of pregnancy was not influenced by treatment either in the parental or in the Fl-generation.

Gestational parameters such as the number of corpora lutea, implantations, resorptions, and number of pups born alive were comparable to concurrent and historical control data in the parental as well as in the Fl-generation.

Weight gain of Fl-pups was normal in the low- and mid-dose groups but slightly decreased in the high-dose group. This decrease became statistically significant at weaning (lactation day 23). The viability of pups from the F1- and F2-generation was not affected by treatment.
2. **Teratology – Rats:**

In a Segment II study, flumazenil was administered by gavage to rats at doses of 0, 15, 50, and 150 mg/kg/day. The test drug was administered to 40 mated female rats/dose from day 7 to day 16 of gestation inclusively; control rats received a similar volume of the vehicle. The study included rearing of the offspring until weaning in order to determine the postnatal effects of prenatally administered flumazenil.

Weight gain by the dams was not impaired and there was no evidence for an adverse effect on the various reproductive parameters (i.e., resorption rate, number of dead fetuses, mean body weight of fetuses, mean crown/rump length and duration of the gestation period). During the postnatal period, the body weight of pups increased uniformly in all dose groups and the incidence of pup mortality was not increased in any of the treatment groups.

External, skeletal, and soft tissue examinations of the fetuses gave no indication of treatment-related teratogenicity. Five fetuses from a single litter in the high-dose group showed multiple skeletal abnormalities (i.e., shortened, poorly ossified, and deformed long bones in fore and hind limbs, missing toes, and enlarged heads).

3. **Teratology – Rabbits:**

In a Segment II study, flumazenil was administered by gavage to rabbits at doses of 0, 15, 50, and 150 mg/kg/day. The test drug was administered to 20 mated female rabbits/dose from day 7 to day 19 of gestation, inclusively; control rabbits received a similar volume of the vehicle. Weight gain of the does during the gestation period, mating success, mean number of corpora lutea, and mean number of implantations were not impaired in any of the groups. The resorption rate noted in the high-dose group (1.6 per pregnant female), was significantly greater than that for the concurrent control (0.7 per pregnant female), but was within the range for historical controls. Examinations of fetuses for malformations revealed no evidence for a teratogenic effect of flumazenil up to a dose of 150 mg/kg/day.

4. **Perinatal and Postnatal – Rats:**

In a Segment III study, flumazenil was administered by gavage to rats at doses of 0, 5, 25, and 125 mg/kg. The test drug was administered to 24 mated females/group from day 16 of gestation until weaning, on day 22 of lactation. A control group received the vehicle.

There were no significant dose- or drug-related differences between the groups in the number of intrauterine and perinatal deaths. Mortality during lactation was increased in the high-dose group (14% versus 7.8% in the control group). From the weanlings in which the organs were weighed, a slight but dose-related increase of liver weights was noted in the mid- and high-dose groups. The physical and functional development of neonates was normal, although there was a slight but statistically significant delay of incisor eruption, ear opening, and auditory startle response in the offsprings of high-dose-treated dams.
Irritation Studies

1. **Venous Irritation – Rabbits:**

   A single injection of 1.0 mL of flumazenil (1 mg/mL, mixed micelles formulation) into the marginal ear vein of 6 New Zealand rabbits did not cause significant irritation of the veins.

2. **Local Tolerance – Rabbits:**

   Five rabbits were given an i.v. injection of 0.5 mL of flumazenil (0.5 mg/5 mL, aqueous formulation) in the direction of the venous flow for the marginal ear veins. Intravenous tolerance was rated as good; only one animal had some reddening in the vicinity of the injection site (without any effect on the vein) on days 1 and 2.

3. **Local Tolerance - Rat Hindquarter Muscle:**

   Intramuscular tolerance was rated as good in 10 rats receiving 0.1 mL of flumazenil (0.5 mg/5mL, aqueous formulation) into the gastrocnemius muscle of each hind limb. Creatinine phosphokinase was elevated relative to baseline at 24 hours after injection in both treated and control animals. The elevations seen in treated rats were somewhat larger than those observed in the control group.

4. **Hemolysis Testing – Dogs:**

   Intravenous administration of 1.0 mL of flumazenil (1 mg/mL, mixed micelles formulation) to 12 dogs did not produce any significant hemolysis.
REFERENCES

Pharmacology

Human Pharmacokinetics

Clinical Pharmacology


**Clinical Use**


**Other**

PART III: CONSUMER INFORMATION

Flumazenil Injection USP

This leaflet is part III of a three-part "Product Monograph" published when Flumazenil Injection, USP was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Flumazenil Injection USP. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
Flumazenil Injection, USP is indicated for the complete or partial reversal of the central sedative effects of benzodiazepines. It may therefore be used in anesthesia and intensive care in the following situations:

- termination of general anesthesia induced and/or maintained with benzodiazepines;
- reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures;
- for the diagnosis and/or management of deliberate or accidental benzodiazepine overdose.

What it does:
Flumazenil is a benzodiazepine-specific antagonist which blocks the central effects of agents that act via the benzodiazepine receptor, by competitive inhibition. The hypnotic-sedative effects of benzodiazepines are rapidly reversed by flumazenil. However, the residual effects may reappear gradually within a few hours, depending on the dose of flumazenil, the time elapsed since the benzodiazepine agonist was given, and the dose and elimination half-life of the previously administered benzodiazepine.

When it should not be used:
- in patients with known hypersensitivity to flumazenil or to benzodiazepines;
- in epileptic patients who have been receiving benzodiazepine treatment for a prolonged period. The abrupt suppression of the protective effect of benzodiazepines may induce convulsions in epileptic patients;
- in patients who are showing signs of serious cyclic antidepressant overdose;
- in patients who have been given a benzodiazepine for a potentially life-threatening condition (e.g., intracranial pressure).

What the medicinal ingredient is:
flumazenil

What the important nonmedicinal ingredients are:
For a full listing of nonmedicinal ingredients, see Part I of the Product Monograph.

What dosage forms it comes in:
Flumazenil Injection, USP is a sterile liquid for intravenous injection and contains 0.1 mg flumazenil per mL of solution. Flumazenil Injection, USP is available in multiple-dose glass vials:
C402405: 5 mL fill in a 6.5 mL vial; packaged in trays of 10 vials
C402410: 10 mL fill in a 10 mL vial; packaged individually

WARNINGS AND PRECAUTIONS

In view of the short duration of action of flumazenil and the possible need for repeat doses, the patient should remain closely monitored until all possible central benzodiazepine effects have subsided.

Flumazenil should be administered only when the continued observation of patients for recurrence of sedation can be assured.

The immediate availability of oxygen, resuscitative equipment and skilled personnel for the maintenance of airway, ventilation and cardiac function should be ensured before the administration of any benzodiazepine or flumazenil.

When used in anesthesiology at the end of surgery, flumazenil should not be given until the effects of neuromuscular blockade have been completely antagonized and careful monitoring of the respiratory depressant effect of opiate analgesics has been assured. After the benzodiazepine has been antagonized with flumazenil, any residual respiratory depressant effect of other agents, such as opiates, should be appropriately treated.

The ability of flumazenil to reverse benzodiazepine-induced respiratory depression is equivocal; in some studies, residual effects of benzodiazepines on respiration were still present despite reversal of sedation.

In patients treated for long periods of time and/or with high doses of benzodiazepines, flumazenil may trigger withdrawal symptoms (e.g., convulsions, agitation, anxiety, emotional lability as well as mild confusion and sensory distortions); rapid intravenous injections should therefore be avoided. Seizures have been reported in patients known to suffer from epilepsy, or severe hepatic impairment, particularly after long-term treatment with benzodiazepines or in cases of mixed-drug overdose. Flumazenil should be used with caution in the Intensive Care Unit because of the increased risk of unrecognized benzodiazepine dependence in such settings.

The dosage of flumazenil should be adjusted carefully in patients suffering from preoperative anxiety or having a history of chronic
or episodic anxiety.

Patients who have received flumazenil to reverse the effects of benzodiazepine sedation should be instructed, if possible in writing, not to drive, operate machinery or engage in any other physically or mentally demanding activity for 24 hours or until the effects of the benzodiazepine have subsided, since the effect of the benzodiazepine may return. Patients should also be warned not to take alcohol, or drugs not prescribed by their physician, until the effects of the benzodiazepines have subsided.

Caution is advised when administering flumazenil to patients with myocardial infarction or cardiac arrhythmias.

In patients with liver insufficiency, the elimination of flumazenil can be delayed. Seizures have been reported in patients known to suffer from severe hepatic impairment, particularly after long-term treatment with benzodiazepines or in cases of mixed-drug overdose.

In patients with increased intracranial pressure, flumazenil may further increase intracranial pressure and decrease cerebral perfusion pressure, or precipitate convulsions.

Particular caution is necessary when using flumazenil in cases of multiple-drug overdosage, since the toxic effects (cardiac arrhythmias and/or convulsions) of other psychotropic drugs, especially cyclic antidepressants, may increase as the effects of benzodiazepines subside.

**INTERACTIONS WITH THIS MEDICATION**

Flumazenil blocks the central effects of benzodiazepines by competitive interaction at the receptor level; the effects of non-benzodiazepines which act via the benzodiazepine receptor, such as zopiclone, triazolopyridazines and others, are also blocked. However, flumazenil does not reverse the effects of drugs that do not act via this route.

The pharmacokinetics of flumazenil are unaltered in the presence of benzodiazepines, and similarly, flumazenil does not affect the kinetics of benzodiazepines.

There is no pharmacokinetic interaction between ethanol and flumazenil.

**PROPER USE OF THIS MEDICATION**

Flumazenil should be administered intravenously by a physician with experience in anesthesiology.

The dose of flumazenil should always be individually titrated to the desired response to avoid abrupt awakening. Particular care is needed with patients who are physically dependent on benzodiazepines, patients who have ingested multiple drugs, and patients who are prone to anxiety.

Flumazenil may be diluted in a glass bottle to a final concentration of 0.05 mg/mL with 0.9% Sodium Chloride Injection, 0.45% Sodium Chloride and 2.5 % Dextrose Injection, 5% Dextrose Injection, or Lactated Ringer’s Injection.

**Reversal of General Anesthesia/Sedation:**

The recommended initial dose is 0.2 mg administered intravenously over 15 seconds. If the desired level of consciousness is not obtained within 60 seconds, a further dose of 0.1 mg can be injected and repeated at 60-second intervals, up to a maximum total dose of 1 mg.

**Known or Suspected Benzodiazepine Overdose:**

For the reversal of excessive sedative effects of benzodiazepines in overdose cases, titrate flumazenil as described below, until the patient clearly responds or until the maximum recommended dose has been reached.

The recommended initial dose is 0.3 mg administered intravenously over 30 seconds, followed by a series of 0.3 mg injections, each administered over a 30-second period, at 60-second intervals. The maximum recommended dose is 2.0 mg.

If drowsiness recurs, an intravenous infusion of 0.1-0.4 mg/hr may be useful. The rate of the infusion should be individually adjusted to the desired level of arousal.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Flumazenil is generally well tolerated. In postoperative use, nausea and/or vomiting are observed, particularly if opiates have also been employed. Flushing has also been noted. If patients are awakened too rapidly, they may become agitated, anxious or fearful. Transient increases in blood pressure and heart rate may also occur.

Excessively and/or rapidly injected doses of flumazenil may induce benzodiazepine withdrawal symptoms such as anxiety attacks, tachycardia, dizziness, and sweating in patients on long-term benzodiazepine treatment.

Although clinical experience with flumazenil is limited, seizures and/or cardiac arrhythmias have been observed in patients who are physically dependent on benzodiazepines, and in multiple-drug overdose, particularly in the presence of tricyclic antidepressants.

Flumazenil has been reported to provoke panic attacks in patients with a history of panic disorders.
### How to Store It

Flumazenil Injection, USP should be stored between 15 °C and 30 °C.

Multidose vial. Discard unused portion 28 days after initial puncture.

Infusion solutions containing flumazenil should be used within 24 hours, and unused portions discarded.

### Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

**3 ways to report:**
- Online at [MedEffect](http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program Health Canada, Postal Locator 0701E Ottawa, ON K1A 0K9


**NOTE:** Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

### More Information

This document plus the full Product Monograph, prepared for health professionals, can be obtained by contacting the sponsor, Fresenius Kabi Canada Ltd., at 1-877-821-7724.

This leaflet was prepared by Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8

Last revised: April 15, 2015

---

### Table: Serious Side Effects, How Often They Happen and What to Do About Them

<table>
<thead>
<tr>
<th>Symptom/effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td><strong>Common</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>agitation</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>crying/tears</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>headache</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>anxiety/anxious feeling</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>seizures/convulsions</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>dizziness</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>nausea</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>vomiting</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>increased blood pressure</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>increased heart rate</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>shivering/cold</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td><strong>Uncommon</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>flushing</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>abnormal heart rate</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>difficulty breathing</td>
<td>T</td>
<td></td>
</tr>
</tbody>
</table>

*This is not a complete list of side effects. For any unexpected effects while taking Flumazenil Injection, USP, contact your doctor or pharmacist.*